Windtree Therapeutics Advances istaroxime with SEC Approval
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Windtree Therapeutics, Inc. (NASDAQ: WINT) is a clinical-stage biopharmaceutical and medical device company headquartered in Warrington, Pennsylvania. Founded in 1992 as Discovery Laboratories, the company develops therapies targeting acute cardiovascular and pulmonary conditions with significant unmet medical needs. Its lead program, istaroxime, is designed to enhance systolic contraction and diastolic relaxation through SERCA2a activation and Na⁺/K⁺-ATPase inhibition.
As of July 14, 2025, WINT shares closed at $0.9331, an increase of 27.82% on a volume of 12,651,483 shares traded on the NASDAQ.
| Ticker | Price (USD) | Change (%) | Volume | Exchange |
|---|---|---|---|---|
| WINT | 0.9331 | +27.82 | 12,651,483 | NASDAQ |
Corporate Structure
Windtree employs between 11 and 50 professionals, according to LinkedIn. Leadership is led by CEO Jed Latkin, who was appointed on December 1, 2024, and possesses nearly 30 years of financial and biotech experience. Supporting him are President and COO Eric Curtis, CMO Steve Simonson, and CFO Jamie McAndrew. The management team oversees research and development, manufacturing, and finance, with Vice President of Technical Operations George Cox responsible for global clinical supplies and logistics.
Istaroxime by Yangfan Xiao
Recent Developments and News
- July 11, 2025: The Securities and Exchange Commission declared effective Windtree’s Form S-1 registration (No. 333-287358), allowing the company to pursue public offerings to enhance its pipeline.
- July 2025: The U.S. Patent and Trademark Office issued a patent (application 18/150,870) covering an istaroxime-containing intravenous formulation for treatment of acute heart failure.
- July 2025: Enrollment reached 20 patients in the SEISMiC C Phase 2 study of istaroxime in Society for Cardiovascular Angiography and Interventions (SCAI) Stage C cardiogenic shock, which will trigger an interim safety analysis.
- Mid-2025: Windtree entered into an agreement with an external U.S. manufacturer to produce Evofem’s hormone-free contraceptive, PHEXXI, at over 50% lower cost by year-end 2026. Early-stage manufacturing is underway with technical transfer activities ongoing.
Financial and Strategic Analysis
Windtree’s stock price increase of 27.82% on July 14 reflects investor interest in its capital-raising and clinical developments. The effectiveness of the Form S-1 allows Windtree to access public markets for funding to support istaroxime’s Phase 3 trials and preclinical SERCA2a activators for chronic heart failure. The new manufacturing contract for PHEXXI is expected to provide non-dilutive revenue, diversifying the company’s cash flow leading up to product approvals.
Key strategic priorities include:
- Advancing istaroxime through Phase 3 trials in acute heart failure and cardiogenic shock.
- Progressing oral and intravenous SERCA2a activators in preclinical development for chronic and acute heart failure.
- Developing precision atypical protein kinase C iota (aPKCi) inhibitors for oncology applications.
- Strengthening the balance sheet via potential equity offerings and revenue from PHEXXI production.
Market Position and Industry Context
Windtree operates in competitive acute care markets where novel therapies address substantial clinical needs. In acute cardiovascular care, few agents target both systolic and diastolic dysfunction, positioning istaroxime as a differentiated candidate pending Phase 3 outcomes. Windtree’s history with Surfaxin and Aerosurf indicates expertise in surfactant technology, although these programs have been deprioritized in favor of oncology and cardiovascular development.
The emerging oncology portfolio focused on targeting aPKCi presents opportunities in both rare and broader indications, albeit it faces competition from established kinase inhibitors. The agreement for PHEXXI production allows Windtree to engage in the contraceptive market, employing a service-revenue model to offset research and development costs.
tl;dr
Windtree’s SEC-effective S-1 (July 11, 2025) enables capital raising for Phase 3 trials of istaroxime. A newly secured U.S. patent enhances formulation exclusivity, and SEISMiC C enrollment of 20 patients has reached the interim safety analysis milestone. The contract to produce PHEXXI at significantly reduced costs is expected to generate revenue by year-end 2026, diversifying the company’s cash flow ahead of critical trial readouts.